ArticleBMC medical genomics2025
Epigenomic signatures of accelerated epigenetic aging are associated with congenital heart disease in newborns.
Article in BMC medical genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundCongenital heart disease (CHD) lesions are the most common birth defects and despite advances in care, are associated with short- and long-term co-morbidities. The exact mechanisms that may influence outcomes in survivors with CHD remain unclear and are likely multi-factorial; exploring the epigenome in these cases may provide novel insights into predictive biomarkers contributing to outcomes. The present study characterizes the impact of CHD on the newborn epigenome through assessments of epigenetic age.
methodsThis is a prospective, single-site case-control pilot study conducted at Children's National Hospital with subjects enrolled from the Washington DC Metropolitan area. Genomic samples were collected between 2018 and 2024 and analyzed using the Illumina MethylationEPIC BeadChip array platform. PedBE was used to assess infant biological age acceleration.
resultsUsing a methylation array approach, we analyzed the epigenetic age of 33 newborns with complex CHD requiring neonatal cardiac surgery and 26 healthy controls. There was a significant accelerated epigenetic age in newborns with CHD (+ 72.9 days) compared to newborns from uncomplicated pregnancies (+ 13.9 days, p < 0.001, unadjusted). Further subgroup analysis within the CHD cohort revealed that both single- (+ 56.6 days) and two-ventricle CHD (+ 64.8 days) displayed significant accelerated epigenetic age, with transposition of the great arteries (TGA) cases having the greatest accelerated age (107.2 days, p = 0.0001). Stepwise analysis of clinical measures in the CHD group revealed significant age acceleration was associated with low blood oxygen saturation.
conclusionsThis pilot study reveals accelerated epigenetic aging in newborns with critical CHD compared to healthy controls. Though the mechanisms behind these findings are not well-defined, the association between postnatal measures of oxygen saturation and epigenetic age suggests hypoxia may play a significant role and should be explored in future studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.